Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.44 |
| ▸ | ADH1C | P00326 | 1/20 | 0.44 |
| ▸ | ADH1A | P07327 | 1/20 | 0.44 |
| ▸ | ADH4 | P08319 | 1/20 | 0.44 |
| ▸ | ADH7 | P40394 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7045966 | 1.00 | ADH1B (0.44) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL333320 | 1.00 | ADH1B (0.44) | ADH1BADH1CADH1AADH4ADH7 | |
| Hydrochloric Acid SCHEMBL7046843 | 0.98 | ADH1B (0.42) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL7045905 | 0.98 | ADH1B (0.47) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL332488 | 0.98 | ADH1B (0.47) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL332393 | 0.98 | ADH1B (0.47) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL7047398 | 0.98 | ADH1B (0.47) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL333039 | 0.98 | ADH1B (0.47) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL332487 | 0.98 | ADH1B (0.47) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL333359 | 0.98 | ADH1B (0.47) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531181-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | Pharma Two B Ltd. (IL) | 2012-12-12 | — | — | EP | claimed |
| US-20120301542-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD. (IL) | 2012-11-29 | — | — | US | claimed |
| CN-102791258-A | Extended release formulations of rasagiline and uses thereof | PHARMA TWO B LTD | 2012-11-21 | — | — | CN | claimed |
| WO-2011095973-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD. (IL) | 2011-08-11 | — | — | WO | claimed |
| EP-1686973-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RES & DEV FOUNDATION (IL) | 2009-03-25 | — | — | EP | claimed |
| EP-1942881-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE | Technion Research and Development of Foundation, Ltd. (IL) | 2008-07-16 | — | — | EP | claimed |
| US-20080090915-A1 | METHOD FOR PREVENTING OR ATTENUATING ANTHRACYCLINE-INDUCED CARDIOTOXICITY | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2008-04-17 | — | — | US | claimed |
| WO-2007039909-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2007-04-12 | — | — | WO | claimed |
| US-20070082958-A1 | Methods for treatment of renal failure | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2007-04-12 | — | — | US | claimed |
| US-20060287401-A1 | Methods for treatment of cardiovascular disorders and diseases | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2006-12-21 | — | — | US | claimed |
| EP-1686973-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) | 2006-08-09 | — | — | EP | claimed |
| US-20050171210-A1 | Compositions and methods for treatment of cardiovascular disorders and diseases | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2005-08-04 | — | — | US | claimed |
| WO-2005051371-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2005-06-09 | — | — | WO | claimed |
| US-6809120-B1 | PROTECTING NORMAL CELLS; OVERCOMING DRUG RESISTANCE AND/OR TOXICITY | UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC. (CA) | 2004-10-26 | — | — | US | claimed |
| EP-0996612-B1 | ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS | UNIV SASKATCHEWAN (CA) | 2003-04-09 | — | — | EP | claimed |
| US-6251950-B1 | ADMINISTERING TO THE PATIENT AN ALIPHATIC-PROPARGYLAMINE OR SALT FOR THE TREATMENT OF ACUTE AND CHRONIC DISEASES IN WHICH CELL DEATH OCCURS BY APOPTOSIS OR FOR THE TREATMENT OF PREMATURE DEGENERATION OF CELLS IN MAMMALS | UNIVERSITY OF SASKATCHEWAN (CA) | 2001-06-26 | — | — | US | claimed |
| EP-0996612-A2 | ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS | University of Saskatchewan Technologies Inc. (CA) | 2000-05-03 | — | — | EP | claimed |
| WO-1999003817-B1 | ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS | UNIV SASKATCHEWAN (CA) | 1999-07-01 | — | — | WO | claimed |
| WO-1999003817-A2 | ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS | UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC. (CA) | 1999-01-28 | — | — | WO | claimed |
| EP-3517103-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | Pharma Two B Ltd. (IL) | 2019-07-31 | — | — | EP | disclosed |
| EP-2531181-B1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD (IL) | 2019-04-10 | — | — | EP | disclosed |
| US-9943489-B2 | Extended release formulations of rasagiline and uses thereof | PHARMATWOB LTD. (IL) | 2018-04-17 | — | — | US | disclosed |
| EP-2433626-B1 | Compositions and methods for treatment of cardiovascular disorders and diseases | TECHNION RES & DEV FOUNDATION (IL) | 2015-11-04 | — | — | EP | disclosed |
| EP-2531181-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | Pharma Two B Ltd. (IL) | 2012-12-12 | — | — | EP | disclosed |
| US-20120301542-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD. (IL) | 2012-11-29 | — | — | US | disclosed |
| CN-102791258-A | Extended release formulations of rasagiline and uses thereof | PHARMA TWO B LTD | 2012-11-21 | — | — | CN | disclosed |
| US-8263655-B2 | Methods for treatment of renal failure | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD (IL) | 2012-09-11 | — | — | US | disclosed |
| EP-1942881-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE | TECHNION RES AND DEV OF FOUNDATION LTD (IL) | 2012-08-08 | — | — | EP | disclosed |
| US-20120095107-A1 | METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2012-04-19 | — | — | US | disclosed |
| EP-2433626-A1 | Compositions and Methods for Treatment of Cardiovascular Disorders and Diseases | Technion Research & Development Foundation Ltd. (IL) | 2012-03-28 | — | — | EP | disclosed |
| US-8097608-B2 | Use of propargylamine or derivative including including N-propargyl-1-aminoindane as protective agent; preventing apoptosis | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2012-01-17 | — | — | US | disclosed |
| WO-2011095973-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD. (IL) | 2011-08-11 | — | — | WO | disclosed |
| EP-1686973-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RES & DEV FOUNDATION (IL) | 2009-03-25 | — | — | EP | disclosed |
| EP-1942881-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE | Technion Research and Development of Foundation, Ltd. (IL) | 2008-07-16 | — | — | EP | disclosed |
| US-20080090915-A1 | METHOD FOR PREVENTING OR ATTENUATING ANTHRACYCLINE-INDUCED CARDIOTOXICITY | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2008-04-17 | — | — | US | disclosed |
| WO-2007039909-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2007-04-12 | — | — | WO | disclosed |
| US-20070082958-A1 | Methods for treatment of renal failure | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2007-04-12 | — | — | US | disclosed |
| US-20060287401-A1 | Methods for treatment of cardiovascular disorders and diseases | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2006-12-21 | — | — | US | disclosed |
| EP-1686973-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) | 2006-08-09 | — | — | EP | disclosed |
| US-20050171210-A1 | Compositions and methods for treatment of cardiovascular disorders and diseases | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2005-08-04 | — | — | US | disclosed |
| WO-2005051371-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2005-06-09 | — | — | WO | disclosed |
| EP-0996612-B1 | ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS | UNIV SASKATCHEWAN (CA) | 2003-04-09 | — | — | EP | disclosed |
| US-6251950-B1 | ADMINISTERING TO THE PATIENT AN ALIPHATIC-PROPARGYLAMINE OR SALT FOR THE TREATMENT OF ACUTE AND CHRONIC DISEASES IN WHICH CELL DEATH OCCURS BY APOPTOSIS OR FOR THE TREATMENT OF PREMATURE DEGENERATION OF CELLS IN MAMMALS | UNIVERSITY OF SASKATCHEWAN (CA) | 2001-06-26 | — | — | US | disclosed |
| EP-0996612-A2 | ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS | University of Saskatchewan Technologies Inc. (CA) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999003817-A2 | ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS | UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC. (CA) | 1999-01-28 | — | — | WO | disclosed |
| US-5840979-A | USEFUL IN THE TREATMENT AND PREVENTION OF DISEASES IN WHICH CELL DEATH OCCURS BY APOPTOSIS | UNIVERSITY OF SASKATCHEWAN (CA) | 1998-11-24 | — | — | US | disclosed |
| US-5840979-A | USEFUL IN THE TREATMENT AND PREVENTION OF DISEASES IN WHICH CELL DEATH OCCURS BY APOPTOSIS | UNIVERSITY OF SASKATCHEWAN (CA) | 1998-11-24 | — | — | US | disclosed |